ArticleFrontiers in pharmacology2020
Cardiovascular Complications of Prostate Cancer Treatment.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Cardiovascular Complications Associated with Uro-Oncology Treatments-A Primer for the Clinician.Diagnostics (Basel, Switzerland) · 2026Review
- The burden of cardiovascular disease in prostate cancer: prevalence, pathophysiology, and implications for integrated care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone.Cardio-oncology (London, England) · 2026Article
- Indian Delphi consensus on cardiovascular risk mitigation in prostate cancer management.Frontiers in oncology · 2026Review
- Evaluating the effects of exercise and phellodendron amurense on cardiac function in a prostate cancer mouse model.Journal of applied physiology (Bethesda, Md. : 1985) · 2025Article
- Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study.Advances in therapy · 2025Article
- Evaluating the Anticancer Properties of Novel Piscidinol A Derivatives: Insights from DFT, Molecular Docking, and Molecular Dynamics Studies.ACS omega · 2024Article
- Exercise and diet support in breast and prostate cancer survivors: findings from focus groups.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer.Current cardiology reports · 2023Review
- Prostate Cancer and Cardiovascular Risk Factors.JACC. CardioOncology · 2023Article
- Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study.British journal of cancer · 2023Article
- Allostatic load and cardiovascular outcomes in males with prostate cancer.JNCI cancer spectrum · 2023Article
- High-quality nursing service system is superior to routine care in the care management of malignancies.American journal of translational research · 2023Article
- Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review.Cancers · 2022Article
- Second generation androgen receptor antagonists and challenges in prostate cancer treatment.Cell death & disease · 2022Review
- Antibody-Drug Conjugates in Uro-Oncology.Targeted oncology · 2022Review
- Article
- Drug Resistance and Cardiovascular Safety of Second-Generation Anti-Androgens in Patients with Advanced Prostate Cancer : Second-Generation Antiandrogen Use in Advanced Prostate Cancer.Galen medical journal · 2022Review
- Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment-A Cardio-Oncology Study.Frontiers in oncology · 2021Article
- Cardiac Biomarkers and Geriatric Assessment in Metastatic Castrate-Resistant Prostate Cancer During Abiraterone Acetate Therapy - A Cardio-Oncology Study.Cancer control : journal of the Moffitt Cancer CenterObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of prostate cancer (PC) is a rapidly evolving field of pharmacology research. In recent years, numerous novel therapeutics that improve survival and ameliorate disease control have been approved. Currently, the systemic treatment for prostate neoplasm consists of hormonal therapy, chemotherapy, immunotherapy, radiopharmaceuticals, targeted therapy, and supportive agents (e.g., related to bone health). Unfortunately, many of them carry a risk of cardiovascular complications, which occasionally pose a higher mortality threat than cancer itself. This article provides a unique and comprehensive overview of the prevalence and possible mechanisms of cardiovascular toxicities of all PC therapies, including state-of-the-art antineoplastic agents. Additionally, this article summarizes available recommendations regarding screening and prevention of the most common cardiac complications among patients with advanced cancer disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.